Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UBS Downgrades Merck & Co to Neutral, Lowers Price Target to $76

UBS analyst Colin Bristow downgrades Merck & Co (NYSE:MRK) from Buy to Neutral and lowers the price target from $98 to $76.
byBenzinga Newsdesk
December 13, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

UBS analyst Colin Bristow downgrades Merck & Co (NYSE:MRK) from Buy to Neutral and lowers the price target from $98 to $76.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts